PerformS technology

PSORIASIS TODAY

Psoriasis is a chronic inflammatory skin disease that manifest both at skin level, with the appearance of plaques and at systemic level involving other organs and leading to the occurrence of other pathologies such as psoriatic arthritis, inflammatory bowel diseases, hypertension and depression. Indeed, psoriasis has a significant impact on the patient’s quality of life and mental health.

Typically, psoriasis onset is between 15-25 years and 50-60 years but it can appear at any age.

It affects about 125 million people worldwide and more than 3 million people in Italy.

The actual therapy involves the use of cortisone-based topical products. These drugs exert a powerful anti-inflammatory activity, but their use must be limited over time due to the side effects (rebound, atrophy, depigmentation).

PSORIASIS: OUR SOLUTION

Our discovery changes the topical treatment for psoriasis. PerFormS Technology is able to ACTIVATE an anti-inflammatory molecule which is produced by our body, like cortisone, but that does not lead to side effects.

We have just successfully completed the validation of the technology and we proved the anti-inflammatory activity on an animal model of psoriasis (C57bl / 6) in which the pathology was induced by preliminary treatment with Imiquimod.

FUTURE SCENARIO

PerFormS Technology can be applied to other inflammatory diseases involving different body districts, such as respiratory, intestinal and joint inflammations, which require an administration route than the topical one.